Advanced Prostate Cancer COE

Patient-Centric Approaches: The Urgent Need for Genetic Testing in Prostate Cancer - Brittany Szymaniak

Details
Alicia Morgans and Brittany Szymaniak address the intricacies of germline genetic testing in prostate cancer. They delve into the current NCCN and AUA guidelines, noting challenges in aligning these with practical implementation. Both experts highlight the lag in prostate cancer genetic testing compared to other cancers like breast and ovarian. They explore alternative models for pre-test and post...

Advancing Genetic Testing in Metastatic Prostate Cancer - Brenda Martone

Details
Alicia Morgans and Brenda Martone delve into the critical role of germline and somatic genetic testing in managing metastatic prostate cancer. Dr. Martone emphasizes the NCCN guidelines, which recommend offering both types of testing to patients with high-risk or metastatic disease. The conversation highlights the importance of family history and the broader implications of germline mutations, not...

Identifying the Right Patients for Treatment with Radium-223 for mCRPC - Brenda Martone

Details
Brenda Martone and Alicia Morgans delve into the nuanced use of Radium for treating patients with metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Martone emphasizes that Radium is not just for alleviating bone pain but can also address other symptoms like fatigue and loss of appetite. She notes that the drug can be used at any point in the treatment continuum, depending on patient need...

NCCN Guidelines Update on Selection of PSMA PET Imaging Agent in Patient Selection for Lutetium-177–PSMA-617 - Oliver Sartor

Details
Alicia Morgans has a conversation with Oliver Sartor regarding updates to the NCCN guidelines concerning patient selection for Lutetium treatment using PSMA PET scans. According to Dr. Sartor, the VISION trial based its approval of PSMA-617 Lutetium-177 on PSMA 11 gallium 68 in patient selection, but other PET scans are equally effective. The choice between PSMA-11 gallium-68 and DCFPYL F18 scans...

PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad

Details
Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Divisi...

Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans

Details
Oliver Sartor is joined by Alicia Morgans to discuss her presentation at the GU ASCO 2022 Annual Meeting on the largest digital survey conducted in patients with prostate cancer, the initial results of an international survey of patients with prostate cancer. The goal of this survey was to map patient experiences, expectations, and attitudes, and to identify challenges and unmet needs in diagnosis...

The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares

Details
Andrey Soares joins Phillip Koo at the 13th International Uro-Oncology Conference in Sao Paulo, Brazil in a conversation on challenges and opportunities in the management of patients with high risk localized disease in Latin America as well as the ARASENS data in the metastatic castration sensitive prostate cancer setting. Dr, Soares elaborates on the work that still needs to be done in Brazil to...

Lessons Learned in the STAMPEDE Trial - Nicholas James

Details
Nicholas James joins Phillip Koo at the 13th International Uro-Oncology Conference in Brazil to discuss his presentation on the lessons learned from the STAMPEDE trial which shed insight into how we can improve the outcomes for men with metastatic prostate cancer. Professor James' lecture focuses on how Latin American countries can implement these lessons in conducting and setting up clinical tria...

Real-World Differences in Outcomes with First-Line Abiraterone Therapy Between African American and White Men with mCRPC - A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the JAMA Oncology article titled "Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone." The authors of this study aimed to investigate the differences in outcomes with first-line abiraterone therapy between African American and non-Hispanic White men with mCRPC in...

The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra

Details
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor and A...